Literature DB >> 12207645

Pharmacogenetics and the future of medical practice.

Klaus Lindpaintner1.   

Abstract

Pharmacogenetic approaches are widely expected to bring about a "revolution" in medicine. While the application of molecular genetic approaches to disease research will provide us with new opportunities for progressively more targeted and, hopefully, more effective treatments, these developments will be evolutionary in nature and will, for their realization, still require the painstaking process that discovering and developing a new drug entails. It is also quintessential for the realization of these promises that we support a more rational understanding and more realistic expectations in the public at large through dialogue and information.

Mesh:

Substances:

Year:  2002        PMID: 12207645      PMCID: PMC1874402          DOI: 10.1046/j.1365-2125.2002.01630.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

Review 1.  Pharmacogenomics: translating functional genomics into rational therapeutics.

Authors:  W E Evans; M V Relling
Journal:  Science       Date:  1999-10-15       Impact factor: 47.728

Review 2.  Pharmacogenetics and future drug development and delivery.

Authors:  A D Roses
Journal:  Lancet       Date:  2000-04-15       Impact factor: 79.321

3.  Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics.

Authors:  S Tan; I P Hall; J Dewar; E Dow; B Lipworth
Journal:  Lancet       Date:  1997-10-04       Impact factor: 79.321

4.  Not quite pharmacogenomics.

Authors:  W A Haseltine
Journal:  Nat Biotechnol       Date:  1998-12       Impact factor: 54.908

5.  HIV-1 infection in a man homozygous for CCR5 delta 32.

Authors:  T R O'Brien; C Winkler; M Dean; J A Nelson; M Carrington; N L Michael; G C White
Journal:  Lancet       Date:  1997-04-26       Impact factor: 79.321

6.  Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment.

Authors:  J M Drazen; C N Yandava; L Dubé; N Szczerback; R Hippensteel; A Pillari; E Israel; N Schork; E S Silverman; D A Katz; J Drajesk
Journal:  Nat Genet       Date:  1999-06       Impact factor: 38.330

7.  Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription.

Authors:  K H In; K Asano; D Beier; J Grobholz; P W Finn; E K Silverman; E S Silverman; T Collins; A R Fischer; T P Keith; K Serino; S W Kim; G T De Sanctis; C Yandava; A Pillari; P Rubin; J Kemp; E Israel; W Busse; D Ledford; J J Murray; A Segal; D Tinkleman; J M Drazen
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

8.  Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing.

Authors:  F D Martinez; P E Graves; M Baldini; S Solomon; R Erickson
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

9.  Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression.

Authors:  D W McGraw; S L Forbes; L A Kramer; S B Liggett
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

10.  Beta2-adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population.

Authors:  J C Dewar; A P Wheatley; A Venn; J F Morrison; J Britton; I P Hall
Journal:  Clin Exp Allergy       Date:  1998-04       Impact factor: 5.018

View more
  8 in total

1.  Testing patients to allow tailored drug treatment.

Authors:  Peter Leman; Shaun Greene
Journal:  BMJ       Date:  2005-02-12

Review 2.  Dyskinesias and levodopa therapy: why wait?

Authors:  Michele Matarazzo; Alexandra Perez-Soriano; A Jon Stoessl
Journal:  J Neural Transm (Vienna)       Date:  2018-02-10       Impact factor: 3.575

3.  CYP2D6 allele distribution in Macedonians, Albanians and Romanies in the Republic of Macedonia.

Authors:  M Kuzmanovska; M Dimishkovska; I Maleva Kostovska; P Noveski; E Sukarova Stefanovska; D Plaseska-Karanfilska
Journal:  Balkan J Med Genet       Date:  2016-07-09       Impact factor: 0.519

4.  Adding Genetic Testing to Evidence-Based Guidelines to Determine the Safest and Most Effective Chronic Pain Treatment for Injured Workers.

Authors:  Brian Meshkin; Katrina Lewis; Svetlana Kantorovich; Natasha Anand; Lisa Davila
Journal:  Int J Biomed Sci       Date:  2015-12

Review 5.  Perspective on the Genetic Response to Antiparasitics: A Review Article.

Authors:  Patricia Alarcon-Valdes; Mariana Ortiz-Reynoso; Jonnathan Santillan-Benitez
Journal:  Iran J Parasitol       Date:  2017 Oct-Dec       Impact factor: 1.012

6.  Optimization of Antidepressant use with Pharmacogenetic Strategies.

Authors:  Clara Torrellas; Juan Carlos Carril; Ramón Cacabelos
Journal:  Curr Genomics       Date:  2017-10       Impact factor: 2.236

7.  The association of CYP2D6 gene polymorphisms in the full-length coding region with higher recurrence rate of vivax malaria in Yunnan Province, China.

Authors:  Herong Huang; Ying Dong; Yanchun Xu; Yan Deng; Canglin Zhang; Shuping Liu; Mengni Chen; Yan Liu
Journal:  Malar J       Date:  2021-03-20       Impact factor: 2.979

8.  What is the impact of the ACE gene insertion/deletion (I/D) polymorphism on the clinical effectiveness and adverse events of ACE inhibitors?--Protocol of a systematic review.

Authors:  M Scharplatz; M A Puhan; J Steurer; L M Bachmann
Journal:  BMC Med Genet       Date:  2004-09-10       Impact factor: 2.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.